Biotek-snakken — Juni 2025
-
-
Recludix Pharma Announces Development Candidate Nomination of First-in-Class Oral STAT6 Inhibitor for Inflammatory Diseases and Achievement of Significant Milestone Under Collaboration with Sanofi
--Completion of GLP toxicology studies associated with a $50 million payment to Recludix under the collaboration with Sanofi -- REX-8756 is a potent and selective oral STAT6 inhibitor that demonstrates complete pathway inhibition and is well tolerated in preclinical studies --Investigational New Drug (IND)-enabling activities ongoing to support IND submission later this year SAN DIEGO, June 02, 2025 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in the discovery of inhibitors of challenging targe
Yahoo Finance (finance.yahoo.com)
-
Biotech financing: divide and reset https://www.nature.com/articles/s41587-025-02723-8 Nature Biotechnology
-
LP90 og Jazzz. Det eneste nye er denne https://saniona.com/newsroom/single-press-release/?slug=saniona-acquires-headquarters-to-secure-long-term-stability
-
Gubra: Udbytteregn er rettidig omhu og tydelig aktionærværdi https://proinvestor.com/boards/127037
-
Pila Pharma aktieemission - næste skridt mod fedmepille
jazzz ja nogen ved hvis noget men vi tager gladelig det hele med Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind